在未活检男性中,多参数磁共振成像后行磁共振引导与经直肠超声引导活检为何及何处漏诊显著性前列腺癌
在转诊中心纳入223例未活检且前列腺特异抗原升高和/或直肠指检异常的男性,全部行多参数MRI和12针系统经直肠超声活检,142例MRI怀疑前列腺癌者行MR引导活检。108例患者共191个病灶中,141个(74%)被任一活检方式定义为显著性前列腺癌,MR引导活检检出105个(74%),经直肠超声活检检出86个(61%)。MR引导活检最常漏诊累及背外侧(58%)的癌,经直肠超声活检最常漏诊累及前部(79%)的癌。
要点
- MR引导活检检出141个显著性病灶中的105个(74%),经直肠超声活检检出86个(61%)。
- MR引导活检漏诊的显著性病灶多累及背外侧(58%)和尖部(37%)。
- 经直肠超声活检漏诊的显著性病灶多位于前部(79%)、前部中段(50%)和前部尖部(23%)。
核心结论
- 两种活检技术均难以检出尖部病灶,MR引导活检最常漏诊累及背外侧(58%)的癌,经直肠超声活检最常漏诊累及前部(79%)的癌。
研究设计与样本
- 在转诊中心连续纳入223例未活检、前列腺特异抗原升高和/或直肠指检异常的男性。
- 全部患者行多参数MRI和12针系统经直肠超声活检,142例MRI怀疑前列腺癌者行MR引导活检。
- 比较MR引导与经直肠超声活检的癌症位置,比例以百分比表示并计算95%置信区间。
主要发现
- 108例显著性前列腺癌患者共191个病灶,其中141个(74%)被MR引导或经直肠超声活检定义为显著性前列腺癌。
- MR引导活检检出141个中的105个(74%),经直肠超声活检检出86个(61%)。
- 经直肠超声活检检出病灶数多于MR引导活检(140 vs 109),但这些病灶常为低危(39%)。
- MR引导活检漏诊的显著性病灶最常累及背外侧(58%)和尖部(37%)。
- 经直肠超声活检漏诊的显著性病灶位于前部(79%)、前部中段(50%)和前部尖部(23%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Knowledge of significant prostate (sPCa) locations being missed with magnetic resonance (MR)- and transrectal ultrasound (TRUS)-guided biopsy (Bx) may help to improve these techniques. OBJECTIVE: To identify the location of sPCa lesions being missed with MR- and TRUS-Bx. DESIGN, SETTING, AND PARTICIPANTS: In a referral center, 223 consecutive Bx-naive men with elevated prostate specific antigen level and/or abnormal digital rectal examination were included. Histopathologically-proven cancer locations, Gleason score, and tumor length were determined. INTERVENTION: All patients underwent multi-parametric MRI and 12-core systematic TRUS-Bx. MR-Bx was performed in all patients with suspicion of PCa on multi-parametric MRI (n=142). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer locations were compared between MR- and TRUS-Bx. Proportions were expressed as percentages, and the corresponding 95% confidence intervals were calculated. RESULTS AND LIMITATIONS: In total, 191 lesions were found in 108 patients with sPCa. From these lesion 74% (141/191) were defined as sPCa on either MR- or TRUS-Bx. MR-Bx detected 74% (105/141) of these lesions and 61% (86/141) with TRUS-Bx. TRUS-Bx detected more lesions compared with MR-Bx (140 vs 109). However, these lesions were often low risk (39%). Significant lesions missed with MR-Bx most often had involvement of dorsolateral (58%) and apical (37%) segments and missed segments with TRUS-Bx were located anteriorly (79%), anterior midprostate (50%), and anterior apex (23%). CONCLUSIONS: Both techniques have difficulties in detecting apical lesions. MR-Bx most often missed cancer with involvement of the dorsolateral part (58%) and TRUS-Bx with involvement of the anterior part (79%). PATIENT SUMMARY: Both biopsy techniques miss cancer in specific locations within the prostate. Identification of these lesions may help to improve these techniques.
引用
- Schouten MG, van der Leest M, Pokorny M, et al. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men? Eur Urol. 2017. PMID: 28063613. doi:10.1016/j.eururo.2016.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。